Neumora Therapeutics, Inc. (NMRA) has entered 2026 with momentum, announcing positive Phase 1b results for its lead candidate NMRA-511 in Alzheimer's disease agitation, along with a pipeline strategy that promises multiple clinical readouts across its neuroscience programs.
The company's story this year begins with NMRA-511, its investigational vasopressin 1a receptor antagonist, which met the primary goal in a Phase 1b signal-seeking study for agitation in Alzheimer's disease, a major unmet need, with limited therapeutic options available.
NMRA-511 demonstrated a 15.7-point reduction on mean CMAI total score, representing a clinically meaningful effect. Patients treated with the drug showed a favorable tolerability profile, with no reports of sedation or somnolence. Building on this success, Neumora plans to evaluate higher doses of NMRA-511 via initiation of a multiple ascending dose expansion cohort in 2026 with a Phase 2/3 program later year.
Alongside this achievement, Neumora highlighted a pipeline designed to deliver multiple readouts across neuropsychiatric and neurodegenerative disorders.
Navacaprant, its lead oral kappa opioid receptor antagonist, continues in Phase 3 development for major depressive disorder. The KOASTAL-2 and KOASTAL-3 trials are expected to deliver a consolidated topline readout in the second quarter of 2026, with expanded enrolment aimed at strengthening efficacy assessment.
Another key program is NMRA-215, a highly brain-penetrant NLRP3 inhibitor prioritised for obesity. Following class-leading preclinical data, Neumora plans to initiate a Phase 1 clinical program in the first half of 2026, with weight loss data anticipated by year-end.
The company is also advancing its M4 positive allosteric modulator franchise for schizophrenia, with NMRA-898 and NMRA-861 in Phase 1 studies. A comprehensive update is expected mid-2026, potentially moving one or both programs forward.
Financially, Neumora remains well-positioned, with cash and equivalents expected to support operations into the third quarter of 2027.
Taken together, NMRA-511's signal-seeking success and the breadth of upcoming milestones across Navacaprant, NMRA-215, and the M4 franchise underscore Neumora's ambition to redefine neuroscience drug development.
NMRA has traded between $0.61 and $3.25 over the past year. The stock is currently trading in the pre-market at $1.83, up 10.81%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.